Table 2.
Characteristics No. (%) |
CMS1 (N = 4) | CMS2 (N = 142) | CMS3 (N = 58) | CMS4 (N = 222) | P |
---|---|---|---|---|---|
Median age (range), years | 56 (48-66) | 61 (35-75) | 61 (34-74) | 60 (29-75) | 0.65 |
Sex | 0.42 | ||||
Male | 2 (50) | 88 (62) | 35 (60) | 119 (54) | |
Female | 2 (50) | 54 (38) | 23 (40) | 103 (46) | |
ECOG PS | 0.26 | ||||
0 | 4 (100) | 128 (90) | 47 (81) | 197 (89) | |
1-2 | 0 | 14 (10) | 11 (19) | 25 (11) | |
Synchronous metastases | 0.64 | ||||
Yes | 4 (100) | 124 (87) | 53 (91) | 201 (91) | |
No | 0 | 18 (13) | 5 (9) | 21 (9) | |
Prior adjuvant chemotherapy | 0.62 | ||||
Yes | 0 | 1 (<1) | 0 | 4 (2) | |
No | 4 (100) | 141 (99) | 58 (100) | 218 (98) | |
Primary tumor site | <0.001 | ||||
Right | 2 (50) | 40 (28) | 26 (44) | 111 (50) | |
Left or rectum | 2 (50) | 102 (72) | 32 (55) | 111 (50) | |
Liver only disease | 0.29 | ||||
Yes | 2 (50) | 46 (32) | 12 (21) | 63 (28) | |
No | 2 (50) | 95 (67) | 46 (79) | 159 (72) | |
Missing data | 0 | 1 (<1) | 0 | 0 | |
Resected primary tumor | <0.001 | ||||
Yes | 2 (50) | 62 (44) | 8 (14) | 191 (86) | |
No | 2 (50) | 80 (56) | 50 (86) | 31 (14) | |
Molecular status | <0.001 | ||||
RAS mutated | 2 (50) | 96 (68) | 38 (66) | 136 (61) | |
BRAF mutated | 1 (25) | 1 (<1) | 7 (12) | 36 (16) | |
RAS and BRAF wild-type | 1 (25) | 41 (29) | 8 (14) | 46 (21) | |
Missing data | 0 | 4 (3) | 5 (8) | 4 (2) | |
Microsatellite status | 0.08 | ||||
MSS/pMMR | 3 (75) | 132 (93) | 57 (98) | 203 (91) | |
MSI-high/dMMR | 1 (25) | 4 (3) | 1 (2) | 13 (6) | |
Missing data | 0 | 5 (4) | 0 | 6 (3) | |
Treatment arm | 0.20 | ||||
Doublet/bev | 3 (75) | 72 (51) | 24 (41) | 123 (55) | |
Triplet/bev | 1 (25) | 70 (49) | 34 (59) | 99 (45) |
bev, bevacizumab; CMS, consensus molecular subtypes; dMMR, deficient mismatch repair; ECOG PS, Eastern Cooperative Oncology Group performance status; MSI-high, high microsatellite instability; MSS, microsatellite stable; pMMR, proficient mismatch repair.
Statistically significant P values are reported in italics.